These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 32538213)

  • 1. RNA in spinal muscular atrophy: therapeutic implications of targeting.
    Singh RN; Seo J; Singh NN
    Expert Opin Ther Targets; 2020 Aug; 24(8):731-743. PubMed ID: 32538213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes.
    Singh RN; Singh NN
    Adv Neurobiol; 2018; 20():31-61. PubMed ID: 29916015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.
    Singh NK; Singh NN; Androphy EJ; Singh RN
    Mol Cell Biol; 2006 Feb; 26(4):1333-46. PubMed ID: 16449646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing regulation in spinal muscular atrophy by an RNA structure formed by long-distance interactions.
    Singh NN; Lee BM; Singh RN
    Ann N Y Acad Sci; 2015 Apr; 1341():176-87. PubMed ID: 25727246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bifunctional RNAs targeting the intronic splicing silencer N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy.
    Osman EY; Yen PF; Lorson CL
    Mol Ther; 2012 Jan; 20(1):119-26. PubMed ID: 22031236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing of the Survival Motor Neuron genes and implications for treatment of SMA.
    Bebee TW; Gladman JT; Chandler DS
    Front Biosci (Landmark Ed); 2010 Jun; 15(3):1191-1204. PubMed ID: 20515750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
    Son HW; Yokota T
    Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene.
    Pao PW; Wee KB; Yee WC; Pramono ZA
    Mol Ther; 2014 Apr; 22(4):854-61. PubMed ID: 24317636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
    Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
    Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving concepts on human SMN pre-mRNA splicing.
    Singh RN
    RNA Biol; 2007; 4(1):7-10. PubMed ID: 17592254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7.
    Cho S; Moon H; Loh TJ; Oh HK; Cho S; Choy HE; Song WK; Chun JS; Zheng X; Shen H
    Biochim Biophys Acta; 2014; 1839(4):306-15. PubMed ID: 24533984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat increases full-length SMN splicing: promise for splice-augmenting therapies for SMA.
    Dominguez CE; Cunningham D; Venkataramany AS; Chandler DS
    Hum Genet; 2022 Feb; 141(2):239-256. PubMed ID: 35088120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of SMN2 Pre-mRNA splicing by antisense U7 small nuclear RNAs.
    Madocsai C; Lim SR; Geib T; Lam BJ; Hertel KJ
    Mol Ther; 2005 Dec; 12(6):1013-22. PubMed ID: 16226920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA.
    Zhang ML; Lorson CL; Androphy EJ; Zhou J
    Gene Ther; 2001 Oct; 8(20):1532-8. PubMed ID: 11704813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.
    Singh NN; Howell MD; Androphy EJ; Singh RN
    Gene Ther; 2017 Sep; 24(9):520-526. PubMed ID: 28485722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy.
    Singh RN; Ottesen EW; Singh NN
    Neurosci Insights; 2020; 15():2633105520973985. PubMed ID: 33283185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.